taurine has been researched along with Astrocytoma in 12 studies
Astrocytoma: Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to evaluate whether taurine detection in short-echo (20 ms) proton magnetic resonance spectroscopy contributes to the noninvasive differential diagnosis between medulloblastoma and cerebellar astrocytoma in children and young adults." | 7.72 | Taurine detection by proton magnetic resonance spectroscopy in medulloblastoma: contribution to noninvasive differential diagnosis with cerebellar astrocytoma. ( Arús, C; Baquero, M; Campistol, J; Capdevila, A; Martínez-Pérez, I; Moreno-Torres, A; Pujol, J, 2004) |
| "The activation of NK1 receptors on U373 MG human astrocytoma cells by substance P (SP) and related tachykinins was accompanied by an increase in taurine release and an accumulation of inositol phosphates." | 7.68 | Tachykinin-stimulated inositol phospholipid hydrolysis and taurine release from human astrocytoma cells. ( Lee, CM; Tung, WL; Young, JD, 1992) |
| "Substance P (SP) stimulated [3H]taurine release from human astrocytoma cells (U-373 MG)." | 7.68 | Effects of tachykinins on [3H]taurine release from human astrocytoma cells (U-373 MG). ( Lee, CM; Tung, WL, 1991) |
| " The concentration of taurine (Tau) in medulloblastomas was 29." | 3.72 | In vivo quantification of the metabolites in normal brain and brain tumors by proton MR spectroscopy using water as an internal standard. ( Harada, K; Houkin, K; Tong, Z; Yamaki, T, 2004) |
| "We sought to evaluate whether taurine detection in short-echo (20 ms) proton magnetic resonance spectroscopy contributes to the noninvasive differential diagnosis between medulloblastoma and cerebellar astrocytoma in children and young adults." | 3.72 | Taurine detection by proton magnetic resonance spectroscopy in medulloblastoma: contribution to noninvasive differential diagnosis with cerebellar astrocytoma. ( Arús, C; Baquero, M; Campistol, J; Capdevila, A; Martínez-Pérez, I; Moreno-Torres, A; Pujol, J, 2004) |
| "The effects of a novel nonpeptide NK1 tachykinin receptor antagonist, SR 140333, on the functional consequences of NK1 receptor activation in a human astrocytoma cell line, U373MG, were investigated." | 3.69 | SR 140333, a novel, selective, and potent nonpeptide antagonist of the NK1 tachykinin receptor: characterization on the U373MG cell line. ( Bordey, A; Emonds-Alt, X; Feltz, P; Gauthier, T; Le Fur, G; Lefevre, IA; Oury-Donat, F; Soubrie, P; Thurneyssen, O, 1994) |
| "The activation of NK1 receptors on U373 MG human astrocytoma cells by substance P (SP) and related tachykinins was accompanied by an increase in taurine release and an accumulation of inositol phosphates." | 3.68 | Tachykinin-stimulated inositol phospholipid hydrolysis and taurine release from human astrocytoma cells. ( Lee, CM; Tung, WL; Young, JD, 1992) |
| "Substance P (SP) stimulated [3H]taurine release from human astrocytoma cells (U-373 MG)." | 3.68 | Effects of tachykinins on [3H]taurine release from human astrocytoma cells (U-373 MG). ( Lee, CM; Tung, WL, 1991) |
| "46 eligible patients with either anaplastic astrocytoma (AA) or glioblastoma (GBM) and clinical and computed-tomography-confirmed relapse following primary surgery and radiotherapy received oral tauromustine 130 mg/m2 every 5 weeks." | 2.67 | Phase II study of tauromustine in malignant glioma. ( Aapro, M; Demierre, B; Gregor, A; Ironside, JW; Malmström, P; Rampling, R; Rye, R; Sellar, R; Stewart, M; Whittle, IR, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tong, Z | 1 |
| Yamaki, T | 1 |
| Harada, K | 1 |
| Houkin, K | 1 |
| Moreno-Torres, A | 1 |
| Martínez-Pérez, I | 1 |
| Baquero, M | 1 |
| Campistol, J | 1 |
| Capdevila, A | 1 |
| Arús, C | 1 |
| Pujol, J | 1 |
| Cheema, TA | 1 |
| Ward, CE | 1 |
| Fisher, SK | 1 |
| Belsey, MJ | 1 |
| Davies, AR | 1 |
| Witchel, HJ | 1 |
| Kozlowski, RZ | 1 |
| Oury-Donat, F | 1 |
| Lefevre, IA | 1 |
| Thurneyssen, O | 1 |
| Gauthier, T | 1 |
| Bordey, A | 1 |
| Feltz, P | 1 |
| Emonds-Alt, X | 1 |
| Le Fur, G | 1 |
| Soubrie, P | 1 |
| Haber, B | 1 |
| Hutchison, HT | 1 |
| Borg, J | 1 |
| Balcar, VJ | 1 |
| Mark, J | 1 |
| Mandel, P | 1 |
| Lee, CM | 2 |
| Tung, WL | 2 |
| Young, JD | 1 |
| Gregor, A | 1 |
| Rampling, R | 1 |
| Aapro, M | 1 |
| Malmström, P | 1 |
| Whittle, IR | 2 |
| Rye, R | 1 |
| Stewart, M | 1 |
| Sellar, R | 1 |
| Demierre, B | 1 |
| Ironside, JW | 1 |
| MacPherson, JS | 1 |
| Miller, JD | 1 |
| Smyth, JF | 1 |
| Snodgrass, SR | 1 |
| Iversen, LL | 1 |
1 trial available for taurine and Astrocytoma
| Article | Year |
|---|---|
Phase II study of tauromustine in malignant glioma.
Topics: Adult; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Drug Administration Schedule; Drug Evalu | 1992 |
11 other studies available for taurine and Astrocytoma
| Article | Year |
|---|---|
In vivo quantification of the metabolites in normal brain and brain tumors by proton MR spectroscopy using water as an internal standard.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Astrocytoma; Brain; Brain Neoplasms; Cerebellar Neoplasms; C | 2004 |
Taurine detection by proton magnetic resonance spectroscopy in medulloblastoma: contribution to noninvasive differential diagnosis with cerebellar astrocytoma.
Topics: Adolescent; Adult; Astrocytoma; Cerebellar Neoplasms; Child; Child, Preschool; Diagnosis, Differenti | 2004 |
Subnanomolar concentrations of thrombin enhance the volume-sensitive efflux of taurine from human 1321N1 astrocytoma cells.
Topics: Animals; Animals, Newborn; Astrocytoma; Brain Neoplasms; Calcium; Calcium-Calmodulin-Dependent Prote | 2005 |
Inhibition of ERK and JNK decreases both osmosensitive taurine release and cell proliferation in glioma cells.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Animals; Anthracenes; Apoptosis; Astrocytoma; Cell | 2007 |
SR 140333, a novel, selective, and potent nonpeptide antagonist of the NK1 tachykinin receptor: characterization on the U373MG cell line.
Topics: Astrocytoma; Binding, Competitive; Calcium; Electric Conductivity; Genes, fos; Humans; Inositol Phos | 1994 |
Uptake of neurotransmitters and precursors by clonal cell lines of neural origin.
Topics: Amino Acids; Aminooxyacetic Acid; Aspartic Acid; Astrocytoma; Biogenic Amines; Cell Line; Cell Membr | 1976 |
Characterization of taurine uptake by neuronal and glial cells in culture.
Topics: Amino Acids; Animals; Astrocytoma; Biological Transport; Cell Line; Kinetics; Neuroblastoma; Neurogl | 1979 |
Tachykinin-stimulated inositol phospholipid hydrolysis and taurine release from human astrocytoma cells.
Topics: Alkaloids; Astrocytoma; Brain Neoplasms; Down-Regulation; Humans; Hydrolysis; Phosphatidylinositols; | 1992 |
Effects of tachykinins on [3H]taurine release from human astrocytoma cells (U-373 MG).
Topics: Astrocytoma; Cell Line; Cyclic AMP; Humans; Isoproterenol; Kinetics; Neurokinin A; Substance P; Tach | 1991 |
The disposition of TCNU (tauromustine) in human malignant glioma: pharmacokinetic studies and clinical implications.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain; Brain Neoplasms; Female; Glioblastoma; Human | 1990 |
Amino acid uptake into human brain tumors.
Topics: Absorption; Alanine; Amino Acids; Aminobutyrates; Aspartic Acid; Astrocytoma; Autoradiography; Brain | 1974 |